C

China Isotope & Radiation Corp
HKEX:1763

Watchlist Manager
China Isotope & Radiation Corp
HKEX:1763
Watchlist
Price: 18.82 HKD -0.37% Market Closed
Market Cap: HK$6B

P/E

16
Current
73%
More Expensive
vs 3-y average of 9.3

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
16
=
Market Cap
HK$5.9B
/
Net Income
¥327.4m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
16
=
Market Cap
HK$5.9B
/
Net Income
¥327.4m

Valuation Scenarios

China Isotope & Radiation Corp is trading above its 3-year average

If P/E returns to its 3-Year Average (9.3), the stock would be worth HK$10.88 (42% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-42%
Maximum Upside
+109%
Average Upside
32%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 16 HK$18.82
0%
3-Year Average 9.3 HK$10.88
-42%
5-Year Average 12.1 HK$14.23
-24%
Industry Average 33.5 HK$39.42
+109%
Country Average 29.6 HK$34.84
+85%

Forward P/E
Today’s price vs future net income

Not enough data available to calculate forward P/E

Market Distribution

Lower than 73% of companies in China
Percentile
27th
Based on 5 557 companies
27th percentile
16
Low
0 — 17.1
Typical Range
17.1 — 57.7
High
57.7 —
Distribution Statistics
China
Min 0
30th Percentile 17.1
Median 29.6
70th Percentile 57.7
Max 43 569.3

China Isotope & Radiation Corp
Glance View

Market Cap
6B HKD
Industry
Health Care

China Isotope & Radiation Corp. engages in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications. The company is headquartered in Beijing, Beijing. The company went IPO on 2018-07-06. The firm also provides radiation sterilization services. The firm is also involved in the design, manufacture and installation of Gama ray irradiation devices. The firm opeartes its businesse mainly through four segments, including the Pharmaceuticals segment, the Radiological Products segment, the Irradiation segment and the Independent Medical Laboratory Services and Others segment, with the Pharmaceuticals segment as the core segment. The Pharmaceuticals segment is engaged in the development, manufacture and sale of radiopharmaceuticals, the Kit for Urea Breath Test and testing instruments, as well as in vitro immunodiagnostic reagents and boxes for imaging diagnosis and treatment.

Intrinsic Value
20.16 HKD
Undervaluation 7%
Intrinsic Value
Price HK$18.82
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett